Vigil Neuroscience

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

• CBCheryl BlanchardDirector
• CBCheryl Blanchard, Ph. D.Director
• BBBruce BoothDirector
• SBSuzanne BruhnDirector
• SGShaan GandhiDirector
• GKGerhard KoenigDirector
• IMIvana Magovcevic-LiebischDirector · Executive Officer
• SPSpyros PapapetropoulosExecutive Officer
• ETEvan ThackaberryExecutive Officer
• MTMary ThistleDirector
• CTClay ThorpDirector
• CVChristopher VerniExecutive Officer
• SVStefan VitorovicDirector
• JZJennifer ZiolkowskiExecutive Officer

• 11 Jun 2026Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Useapplication
• 04 Jun 2026Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonistsapplication
• 25 Dec 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Useapplication
• 23 Oct 2025Treatment Of Diseases Related To Colony-stimulating Factor 1 Receptor Dysfunction Using TREM2 Agonistsapplication
• 02 Oct 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Useapplication
• 30 Sept 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Usegranted
• 11 Sept 2025Treatment Of Diseases Related To Atp-binding Cassette Transporter 1 Dysfunction Using TREM2 Agonistsapplication
• 03 Jun 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Usegranted
• 18 Mar 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Usegranted
• 06 Feb 2025Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Useapplication
• 16 Jan 2025ANTI-TREM2 Antibody And Uses Thereofapplication
• 19 Sept 2024Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Useapplication

• 07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
• 30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
• 30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
• 29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
• 26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
• 26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.